The rapidly emerging role of monoclonal
antibodies in the therapeutic arsenal for
gastrointestinal malignancies has offered
new hope in the management of these
diseases. The specificity of these agents
as targeted therapy has shown increasing
fulfillment of their potential for treatment.
To maximize this potential, communication
of the fruits of research is needed to clarify
their role for the practitioner. This is a continuing medical education report of trials presented at the 2009 American Society of Clinical Oncology meeting, and several earlier meetings.
Walter Landers, President and owner of Photon Communications, Inc. is a medical and science writer with over 30 years experience in the health care field. In 2003 he founded Photon Communications and has written many medical monographs, news publications, educational slide programs, clinical papers, symposia and medical meeting reports. He seeks free lance writing assignments in his areas of expertise that encompass a variety of medical disciplines.